Intra-Cellular Therapies (ITCI) Holds Steady Near 52-Week High Amidst Trading Frenzy
NEW YORK – Shares of Intra-Cellular Therapies, Inc. (NasdaqGS: ITCI) closed completely flat on Monday, April 1st, despite experiencing exceptionally high trading volume throughout the session.
As of the market close at 4:00:01 PM EDT, ITCI stock stood at
131.87∗∗.Thismarked∗∗zerochange(0.00 or 0.00%) compared to its previous closing price, also $131.87.
While the closing price showed no movement, the trading day itself was highly active. The stock opened slightly higher at $131.92. Notably, the closing price sits just shy of its 52-week high of $131.98, indicating the stock finished the session near its peak valuation over the past year. The 52-week low for the stock is $64.09.
Perhaps the most significant data point was the massive trading volume. Over 16 million shares of ITCI were traded during the session, vastly exceeding the average volume of approximately 3.63 million shares. This surge in activity suggests significant investor interest or perhaps a specific event influencing trading, even though it ultimately resulted in a neutral closing price.
Intra-Cellular Therapies, with an intraday market capitalization of around
14.05billion,currentlyhasanegativeEPS(TTM)of−0.73 and does not pay a dividend. Analyst estimates put the 1-year target at $132.00, very close to its current level. The next earnings report window is currently indicated between May 5th and May 9th, 2025.
